Share on StockTwits

Aldeyra Therapeutics (NASDAQ:ALDX) Director C. Boyd Clarke bought 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were purchased at an average price of $3.69 per share, with a total value of $11,070.00. Following the transaction, the director now directly owns 15,500 shares of the company’s stock, valued at approximately $57,195. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Separately, analysts at Aegis initiated coverage on shares of Aldeyra Therapeutics in a research note on Thursday, June 19th. They set a “buy” rating and a $35.00 price target on the stock.

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) traded up 0.26% on Friday, hitting $3.85. The stock had a trading volume of 1,990 shares. Aldeyra Therapeutics has a 1-year low of $3.00 and a 1-year high of $8.222. The stock has a 50-day moving average of $5.41 and a 200-day moving average of $6.03. The company’s market cap is $24.0 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.56) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.53) by $1.03. Analysts expect that Aldeyra Therapeutics will post $-1.49 EPS for the current fiscal year.

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.